Please login to the form below

Not currently logged in
Email:
Password:

hereditary angioedema

This page shows the latest hereditary angioedema news and features for those working in and with pharma, biotech and healthcare.

Shire bags US approval for constipation drug Motegrity

Shire bags US approval for constipation drug Motegrity

Shire isn’t viewed as having a particularly strong late-stage pipeline, but it recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE)

Latest news

  • Shire’s angioedema drug Takhzyro claims EU approval Shire’s angioedema drug Takhzyro claims EU approval

    Approval shortly follows a green light in the US. Shire has been granted approval by the EMA for rare disease drug Takhzyro, a blockbuster-in-waiting for the rare disease hereditary ... angioedema (HAE).

  • Shire’s angioedema drug Takhzyro recommended in Europe Shire’s angioedema drug Takhzyro recommended in Europe

    Takhzyro has been recommended for prevention of recurrent attacks of hereditary angioedema (HAE) a rare, genetic disorder that results in recurring attacks of oedema in parts of the body, including the

  • Shire claims US okay for HAE blockbuster-in-waiting Shire claims US okay for HAE blockbuster-in-waiting

    FDA approves Takhzyro as a preventative measure for HAE attacks. Shire has the first approval in hand for its new hereditary angioedema drug lanadelumab, getting the nod from the FDA for ... community. “HAE attacks are painful, debilitating, and

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    Shire recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) therapy Cinryze and has three new therapies filed for approval, namely lanadelumab for

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    Shire could be months away from its first regulatory approval for hereditary angioedema (HAE) candidate lanadelumab as the EMA starts an accelerated review of the drug. ... The antibody - which targets and inhibits plasma kallikrein - is intended as a

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • ‘How is your day?’ ‘How is your day?’

    These are: Primary Immunodeficiency Diseases (PID – causes severe infections); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP – causes of loss of limb function/disability); bleeding disorders (haemophilia and related conditions);

  • Deal Watch August 2016 Deal Watch August 2016

    151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor) for treatment of acute Hereditary Angioedema with sales of $25m.

  • Deal Watch February 2016 Deal Watch February 2016

    Annapurna brings a portfolio of four AAV-based gene therapy programmes at the preclinical stage for alpha-1 antitrypsin deficiency, hereditary angioedema, cardiomyopathy associated with Friedreich's ataxia and severe allergy.

  • Deal Watch November 2015 Deal Watch November 2015

    hereditary angioedema (HAE). ... US. Abbreviations: HAE, Hereditary angioedema. 14th December 2015.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Viropharm / Shire. Acquisition. Orphan drugs including Cinryze for prophylactic. treatment of hereditary angioedema.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics